NCNA | tickerfilter.com

Fundamental analysis

18%

Profitability 18%

Dept financing 2%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-3.56%

1 Month

30.72%

3 Months

-32.61%

6 Months

-46.02%

1 Year

178.17%

2 Year

-45.61%

Key data

Stock price

$2.17

P/E Ratio

0.00

DAY RANGE

$2.13 - $2.29

EPS

-$0.01

52 WEEK RANGE

$0.03 - $7.22

52 WEEK CHANGE

$143.82

MARKET CAP

9.673 M

YIELD

N/A

SHARES OUTSTANDING

2.643 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-15-2025

BETA

2.40

PUBLIC FLOAT

AVERAGE 10 VOLUME

$25,515

AVERAGE 30 VOLUME

$45,769

Company detail

CEO: Hugh S. Griffith
Region: US
Website: nucana.com
Employees: 30
IPO year: 2017

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

NuCana plc engages in the development of products for the treatment of cancer. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil.

NCNA - NuCana plc